Nevertheless, emerging evidence underscores the clinical challenge of primary or secondary resistance to ALK inhibitors during treatment, necessitating a shift to second- or third-generation ALK-TKIs and the meticulous monitoring of NSCLC patients on ALK-TKIs through repeated molecular testing [57]. Here, ALK is linked to non-small cell lung carcinoma.